WADA – World Anti-Doping Agency
Montreal, 8 November 2018 – The World Anti-Doping Agency (WADA) has confirmed the partial suspension of the accreditation of the Doping Control Laboratory at the Karolinska University Hospital (Stockholm Laboratory) as it relates to the gas chromatography combustion isotope ratio mass spectrometry (GC/C/IRMS) method. The disciplinary proceeding confirmed a non-conformity with the International Standard for Laboratories (ISL) for this specific method and the imposed provisional partial suspension announced on 2 August 2018.
The partial suspension will remain in place for a period of six months from the original notification date of the provisional suspension decision (1 August 2018) or until such time as the Chairman of the WADA Executive Committee decides to reinstate the laboratory’s accreditation on the basis of evidence that the necessary improvements have been implemented for a fully compliant method.
The Stockholm Laboratory’s accreditation had been provisionally suspended in August pending disciplinary proceedings being carried out. The Laboratory has 21 days to appeal to the Court of Arbitration for Sport should it so wish.
It is important to note that, during the partial suspension, the Stockholm Laboratory may continue carrying out its regular anti-doping activities, as per the ISL. However, all routine samples that require GC/C/IRMS analysis shall be securely transported with a demonstrable chain of custody to another WADA-accredited laboratory. This is in order to ensure continued high quality sample analysis, which also helps preserve athletes’ confidence in this process and of the wider anti-doping system.
According to the ISL, WADA is responsible for accrediting and re-accrediting anti-doping laboratories, thereby ensuring that they maintain the highest quality standards. This monitoring process is conducted in conjunction with International Organization for Standardization (ISO) assessment by independent national accreditation bodies that are full members of the International Laboratory Accreditation Cooperation (ILAC). Whenever a laboratory does not meet ISL requirements, WADA may suspend the laboratory’s accreditation.
Montreal, 8 November 2018
As the end of the year is fast approaching, the World Anti-Doping Agency (WADA) wishes to remind you that the 2019 List of Prohibited Substances and Methods (List) comes into force on 1 January 2019.
As Signatories of the World Anti-Doping Code (Code), Anti-Doping Organizations are expected to take appropriate steps to distribute the 2019 List to their members and constituents and to ensure that athletes and entourage have been adequately informed of any changes to the List that may affect them.
As such, we wish to draw your attention to the Summary of Major Modifications and Explanatory Notes that was sent to you as part of our media release of 28 September. Several examples were added to existing classes this year, in particular:
Example of endogenous anabolic androgenic steroids: epiandrosterone (3β-hydroxy-5α-androstan-17-one), available in some nutritional supplements.
Examples of Hypoxia-inducible factor (HIF) activating agents: daprodustat (GSK1278863) and vadadustat (AKB-6548).
Example of beta-2-agonist: tretoquinol (trimetoquinol), an ingredient commonly found in oral cold and flu medications, particularly in some countries in Asia.
Examples of aromatase inhibitors: 2-androstenol (5α-androst-2-en-17-ol), 3-androstenol (5α-androst-3-en-17-ol) and 3-androstenone (5α-androst-3-en-17-one).
Examples of S4.4: myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab), myostatin-binding proteins (e.g. follistatin, myostatin propeptide), agents reducing or ablating myostatin expression, activin receptor IIB competitors such as e.g. decoy activin receptors (e.g. ACE-031), anti-activin receptor IIB antibodies (e.g. bimagrumab), and activin A-neutralizing antibodies.
Additional analogues of methylhexaneamine: 5-methylhexan-2-amine (1,4-dimethylpentylamine) and 3-methylhexan-2-amine (1,2-dimethylpentylamine).
Should you have any questions or concerns regarding the above-mentioned modifications, please get in touch with your usual WADA contact.
We thank you for your cooperation and ongoing commitment to Clean Sport.
World Anti-Doping Agency
Montreal, 31 October 2018 – From 24-25 October 2018, the World Anti-Doping Agency (WADA) held its second Global Education Conference in Beijing, China, which was graciously hosted by the China Anti-Doping Agency (CHINADA) in partnership with the United States Anti-Doping Agency (USADA).
Under the theme ‘Innovation, Harmonization and Cooperation’, the Conference convened over 150 participants, from over 70 countries, representing National Anti-Doping Organizations (NADOs); Regional Anti-Doping Organizations (RADOs); National and International Federations; National Olympic Committees; and, Research Institutions. Emceed by Malian basketball Olympian and WADA Education Committee member, Kady Kanouté Tounkara, Conference participants were welcomed and joined by Honorable Sport Minister, Mr. Gou Zhongwen; Vice Sport Minister, Mr. Li Yingchuan; Executive Director General, CHINADA, Mr. Chen Zhiyu; Dr. Edwin Moses, USADA Board Chair and Chair of WADA’s Education Committee; and, Sir Craig Reedie, WADA President.
Together, anti-doping practitioners, researchers and other stakeholders involved in clean sport, examined emerging trends; contributed to development of WADA’s new International Standard for Education and examined how Anti-Doping Organizations (ADOs) could enhance their education programs and, ultimately, strengthen the global anti-doping program, while keeping the athlete at the center of their strategies.
As outlined in the Agenda, day one of the Conference addressed the athlete’s perspective, including the WADA Athlete Committee’s development of an Anti-Doping Charter of Athlete Rights; the role of education in clean sport programs; as well as, roundtable analysis of the International Standard for Education. Day two of the Conference consisted of presentations and workshops regarding existing and emerging education programs and materials; and, provided sessions tailored to specific stakeholders.
In his address to Conference participants, WADA President Sir Craig Reedie thanked CHINADA for hosting the vitally important Conference and thanked USADA for its partnership. He expressed how heartening it was to see such great attendance from those responsible for anti-doping education around the world and said: “Traditionally, the anti-doping movement relied on detection and deterrence to enforce clean sport. However, more and more, it is becoming clear to WADA and the wider anti-doping community of the need to implement longer-term solutions to educate today’s athletes and future generations on doping. Accordingly, one of WADA’s key priorities is to increase and enhance research-led anti-doping education including the development of an International Standard for Education.
The International Standard, which will elevate the status of education to ensure a requirement for ADOs to deliver effective education programs, will also:
Enhance and clarify the definitions of education, information, prevention and values-based education (ethical rationales);
Define roles and responsibilities of stakeholders;
Ensure enhanced cooperation between stakeholders; and
Emphasize the need to plan, evaluate and implement education programs effectively.
This is a hugely important step towards the advancement of education across the world and is another way in which WADA is helping to create a level playing field for athletes to compete clean. So, whether it is athlete outreach at major events, online courses that help athletes understand their rights and responsibilities, training of educators or a regulatory framework to ensure it all happens in the right way, WADA will continue to provide an education program worthy of an ethical and values-based sporting world.”
Mr. Chen Zhiyu, Executive Director General, CHINADA said: “CHINADA highly appreciates and fully supports WADA in developing and implementing the International Standard for Education. China carries out mandatory education on athletes and their support personnel before they enter the national team and represent their country. Today, CHINADA has a fully developed system, contents, procedure and platform to support this work. We are pleased to have the opportunity to share this experience with our colleagues from around the world, to improve the effectiveness of anti-doping education and the global anti-doping program.”
Dr. Edwin Moses, USADA Board Chair and Chair of WADA’s Education Committee said: “I am privileged to support the unwavering commitment of those striving to empower fair play and ethical sport. This week’s Conference offers a rare opportunity to build synergy as a global movement and to further develop and strengthen cooperative partnerships. As we continue to collaborate and find inspiration in shared values, anti-doping educational thought leaders are seeking to explore rigorous best practices and evidence-based theories to inform our practical educational applications. This is critically important work.”
At the end of day two, Conference participants were presented with a declaration surmising the key themes to emerge, which will be published shortly, that is aimed at advancing the Clean Sport movement. It includes such principles as ensuring: that the athletes’ voice is engaged and that their rights are protected; that the International Standard is developed, implemented and supported by ADOs; that ADOs work together to provide easy access to education tools; and, that ADOs continue to collaborate on best practices to further resources and goals; and, advance education.
Montreal, 9 November 2018
The World Anti-Doping Agency (WADA) wishes to remind you that the 15th edition of its Annual Symposium will be held on Wednesday, 13 March and Thursday, 14 March 2019 at the SwissTech Convention Center in Lausanne, Switzerland. Contrary to recent years, the Symposium will be a two day event versus three in light of the World Conference on Doping in Sport that will be held in November 2019, in Katowice, Poland.
The WADA Symposium, which is the main event on the annual global anti-doping calendar, is a unique and practical event that offers anti-doping stakeholders the opportunity to gather, interact and learn from one another. The Symposium is designed for anti-doping practitioners from International Federations, National and Regional Anti-Doping Organizations and Major Event Organizers; representatives from Governments, Athlete Commissions, WADA-accredited laboratories and Athlete Passport Management Units; as well as, other stakeholders such as the media, researchers and service providers that are integral to clean sport.
Please note that further details, including a draft agenda and logistical information, will be provided when registration opens end November 2018.
In the meantime, feel free to send any questions or input related to the Symposium to WADA’s Event Manager, Ms. Anaïs Rodriguez, at firstname.lastname@example.org.
World Anti-Doping Agency
Montreal, 28 September 2018 – Today, the World Anti-Doping Agency (WADA) publishes the 2019 List of Prohibited Substances and Methods (List); the 2019 Summary of Major Modifications and Explanatory Notes; and the 2019 Monitoring Program. The List, which was approved by WADA’s Executive Committee (ExCo) on 20 September 2018, comes into force on 1 January 2019.
The List, which is one of six International Standards that are mandatory for all Signatories of the World Anti-Doping Code (Code), designates what substances and methods are prohibited both in- and out-of-competition, and which substances are banned in particular sports.
WADA Director General Olivier Niggli said: “WADA is pleased to announce the publication of the 2019 Prohibited List. Updated annually, it is one of the cornerstones of the global anti-doping program. Every year, we review the List in consultation with a wide range of stakeholders. It is vital that we stay ahead of those that endeavor to cheat the system so in reviewing the List, experts review sources such as scientific and medical research, trends, and intelligence gathered from law enforcement and pharmaceutical companies.”
The List is released three months ahead of it taking effect so that athletes and their entourage can acquaint themselves with any modifications. Ultimately, athletes are responsible for the substances in their body and the methods on the List; and, athlete entourage are also liable for anti-doping rule violations if determined to be complicit. Consequently, if there is any doubt as to the status of a substance or method, it is important that they contact their respective Anti-Doping Organization (International Federation or National Anti-Doping Organization) for advice.
The List’s annual revision process is led by WADA, beginning with an initial meeting in January and concluding with the publication of the List by 1 October. This is an extensive consultation process that includes WADA’s List Expert Group gathering information, circulating a draft List among stakeholders, taking their submissions into consideration and revising the draft, followed by review by the Agency’s Health, Medical and Research (HMR) Committee.
The HMR Committee then makes its recommendation to the WADA ExCo, which approves the List during its September meeting.
For a substance or method to be added to the List, it must be determined that it meets two of the following three criteria:
It has the potential to enhance or enhances sport performance
It represents an actual or potential health risk to the athletes
It violates the spirit of sport
It should be noted that for athletes who have a legitimate medical reason for using a prohibited substance or method that is on the List, they may be accommodated if they meet the criteria outlined in the International Standard for Therapeutic Use Exemptions (ISTUE). The TUE process has overwhelming acceptance from athletes, physicians and anti-doping stakeholders worldwide.
Languages and Formats
The 2019 Prohibited List; the 2019 Summary of Modifications and Explanatory Notes; and the 2019 Monitoring Program are available for download on WADA’s website in English and French with Spanish to follow shortly.
Stakeholders wishing to translate the List into other languages are kindly asked to signal their interest at email@example.com, by 27 October. If interested, WADA would provide the necessary files and, once the translation is finalized, would make the List available on the Agency’s website.
The List’s mobile-friendly digital edition will go live on 1 January 2019.
Montreal, 4 October 2018
Please note that, on 11 September 2018, the World Anti-Doping Agency’s (WADA’s) Technical Document for Sport Specific Analysis Expert Group (TDSSA EG) met in Montreal to review the level of TDSSA implementation by Anti-Doping Organizations (ADOs), and to confirm upcoming changes to the mandatory application of certain components of the TDSSA, scheduled to come into force on 1 January 2019. As a result, the TDSSA EG will recommend the following to WADA’s Executive Committee (ExCo):
The TDSSA EG confirmed that the mandatory implementation of the haematological module of the Athlete Biological Passport (ABP) for the sports/disciplines with an Erythropoiesis Stimulating Agents’ (ESAs) Minimum Level of Analysis (MLA) of 30% or greater will commence on 1 January 2019 and recommends that the following mandatory criteria apply:
The mandatory implementation of the ABP haematological module shall apply to all athletes from those sports/disciplines with an ESAs MLA of 30% or greater (as identified in the TDSSA) who are part of the ADO’s Registered Testing Pool (RTP).
The program shall be compliant with all applicable ABP Technical Documents and International Standards, including the International Standard for Testing and Investigations (ISTI) and the Technical Document for Athlete Passport Management Units (TD-APMU).
At a minimum, an average of three blood ABP tests shall be planned annually across all athletes from those sports/disciplines with an ESAs MLA of 30% or greater who are part of an ADO’s RTP and therefore part of an ADO’s ABP haematological module program.
The distribution of these tests shall be carried out according to the status of the athlete’s Passport, as well as any intelligence the ADO may have access to and the recommendations of the APMU, so that athletes with atypical/suspicious Passports receive more tests than those with normal Passports.
The mandatory implementation of the Growth Hormone (GH) MLAs for all sports/disciplines will be postponed until the endocrine module of the ABP is ready for implementation.
The stakeholders’ consultation process for a review of the TDSSA will commence in early 2019.
[More information can be found in the Summary of Outcomes.]
On 14 November 2018, WADA’s ExCo will meet and, among other things, review the proposed recommendations and relevant amendments to the TDSSA. This will result in a revised version of the document that will be circulated to relevant stakeholders for information shortly after its approval.
ADOs that have questions or comments regarding these amendments are encouraged to contact WADA at firstname.lastname@example.org by 16 October 2018.
World Anti-Doping Agency
An introduction and overview on Anti-Doping.
What is Doping
According to the CPISRA Anti Doping Rules compliant to WADA Code, Doping is defined as:
- Presence of a prohibited Substance or its metabolites or markets , as defined in the WADA Prohibited List in an athlete’s bodily specimen, except when in agreement with a TUE granted for the particular substance.
- Use or attempted use of a Prohibited Substance or Methods.
- Tampering or attempting to temper with any part of Doping Control.
- Violation of applicable requirements regarding Athlete availability for Out-of-Competition Testing for RTP (Registered Testing Pool) athletes.
- Possession or trafficking of Prohibited Substances and Methods.
- Administration or attempted administration of a Prohibited Substance or Method to any athlete , or assisting ,encouraging ,aiding , abetting , covering up or any other type of complicity involving an anti-doping rule.
- Administration or Attempted Administration to any Athlete In-Competition of any Prohibited Substance or Prohibited Method, or Administration or Attempted Administration to any Athlete Out-of-Competition of any Prohibited Substance or any Prohibited Method that is Prohibited Out-of-Competition
–Complicity : Assisting, encouraging, aiding, abetting, conspiring, covering up or any other type of intentional complicity involving an anti-doping rule violation.
–Prohibited Association : Association by an Athlete or other Person subject to the authority of an Anti-Doping Organization in a professional or sport-related capacity with any ineligible Athlete / Support Person because of an Anti-Doping rule Violation or equivalent case.
Why is Doping Prohibited
The sports regulations prohibit Doping. Any violation of this rules, be it voluntary or not, constitutes a failure to respect the principle of equal opportunities and, therefore, a disrespect of the sports ethics.
Moreover, the consumption of substances which improve performances can put health in danger. The athlete who has resort to Doping doesn’t harm only himself but he also negatively affects sports as a whole.
What are the tasks of the CPISRA Anti-Doping Committee
In 2005, CPISRA constituted a Committee for the fight against Doping charged of the execution of controls and the surveillance of the tests. This committee is responsible for education of CP athletes concerning anti doping, for the conception and the respect of the anti doping rules, for the diffusion of the Prohibited list , for the formation and perfection of the controllers and also the provision information and advice. Its activities are defined through the Anti Doping Committee Statue.
What about medicines provided on order?
The athlete who must follow a treatment should draw the attention of his/her physician and/or pharmacist to the list of the relevant Doping substances.
If he/she obtains medicines from abroad, he/she must take care of their composition which is mentioned on the note devoted to the patients. The ideal would be to carry away his/her own medicines.
Each athlete should establish, with the help of his/her physician or pharmacist, a personal list of the medicines that he can consume in case of illness- personal medication notebook, this would prevent him from absorbing prohibited substances involuntarily.
The Therapeutic Use Exemption (TUE)
A TUE may be granted to an Athlete permitting the use of Prohibited Substance or Prohibited Methods as defined by the Prohibited List for the following reasons:
-The Athlete would experience a significant impairment to health if the Prohibited Substance or Prohibited Method would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of usual health following the treatment of a legitimate medical condition.
-There is no reasonable therapeutic alternative to the Use of the otherwise Prohibited Substance or Prohibited Method.
-The necessity for the Use of the otherwise Prohibited Substance or Prohibited Method cannot be a consequence , wholly or in part , of the prior non –therapeutic Use of substances from the Prohibited List.
How long do the medicines remain detectable in urine?
What is an anti-doping control?
An anti-doping control consists in analyzing, by accredited laboratories, the urine or blood withdrawals of selected athletes in order to track down the prohibited substances. The discovery of such substances results in tacking disciplinary measures against the athlete. Anti-doping control assures the respect of equal opportunities in competition.
Who is submitted to the controls
Who is responsible for anti-doping controls?
Who is in charge of controls?
During the controls, what about disabled athletes?
What does it occur to urine (or blood) withdrawals?
Are the sample of urine (or blood) safe from manipulation?
Are the tests unfailing?
What happens when the result of controls it is negative?
What happens when the result of controls is positive?
The results of Out of competition testing are announced directly by the CPISRA Anti Doping Committee to the athlete.
The athlete can ask in writing for an analysis of the sample B. He has the right to attend this analysis accompanied by an expert and /or a trustworthy person. If the result is negative, the control is declared negative. On the other hand, if the result confirms the one gotten from sample A, the control is declared positive.
The possible sanctions are decided according the CPISRA anti doping rules and applied by the federation of the relevant athlete. Before, the athlete has the right to express himself and to have knowledge of the file. The case must remain confidential until the first instance decision.
It is possible to protest a first instance decision. The protest can be forwarded to an unbiased arbitration court, like WADA and Sport Arbitrary Tribunal in Lausanne.